Patient input required for a Cochrane protocol on an injectable drug (omalizumab) for asthma
Omalizumab is one of a number of monoclonal antibody therapies for asthma to emerge over the last decade or so. They are recommended as options for those with severe asthma in international guidelines. Accurate descriptions of the risks and any possible benefits of drugs like omalizumab are required to allow adults and children with asthma and their clinicians decide whether to choose and to choose between monoclonal therapies.
Patients with severe asthma whose asthma is poorly controlled may benefit from omalizumab given via injection (subcutaneously).
If you have a diagnosis of asthma this task would be ideal for you. Equally, if you care for someone with asthma we would like to hear from you. We want to gain perspectives on both readability and whether this review is answering the needs of people with asthma around the world. We are especially keen to get a patients' views so we can try to ensure that the Cochrane Review is as relevant as possible to people making decisions about their health.